|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Procainamide#Clinical Studies]] |
| {{Propafenone}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Clinical Studies==
| |
| | |
| In 2 randomized, crossover, placebo-controlled, double-blind trials of 60 to 90 days’ duration in subjects with paroxysmal [[supraventricular arrhythmias ]](paroxysmal atrial fibrillation/flutter [PAF], or paroxysmal [[supraventricular tachycardia]] [PSVT]), propafenone reduced the rate of both [[arrhythmias]], as shown in Table 3.
| |
| {|
| |
| |[[File:rythmol06.jpg|thumb|600px]]
| |
| |}
| |
| The patient population in the above trials was 50% male with a mean age of 57.3 years. Fifty percent of the subjects had a diagnosis of PAF and 50% had PSVT. Eighty percent of the subjects received 600 mg/day propafenone. No subject died in the above 2 trials.
| |
| | |
| In US long-term safety trials, 474 subjects (mean age: 57.4 + 14.5 years) with [[supraventricular arrhythmias]] [195 with PAF, 274 with PSVT and 5 with both PAF and PSVT] were treated up to 5 years (mean: 14.4 months) with propafenone. Fourteen of the subjects died. When this mortality rate was compared with the rate in a similar patient population (n = 194 subjects; mean age: 43.0 + 16.8 years) studied in an [[arrhythmia]] clinic, there was no age-adjusted difference in mortality. This comparison was not, however, a randomized trial and the 95% confidence interval around the comparison was large, such that neither a significant adverse or favorable effect could be ruled out.
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Ketones]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Alcohols]]
| |
| [[Category:Amines]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |